Article
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Nov 2024
Jhaveri Komal L, Accordino Melissa K, Bedard Philippe L, Cervantes Andrés, Gambardella Valentina, Hamilton Erika, Italiano Antoine, Kalinsky Kevin, Krop Ian E, Oliveira Mafalda, Schmid Peter, Saura Cristina, Turner Nicholas C, Varga Andrea, Cheeti Sravanthi, Hilz Stephanie, Hutchinson Katherine E, Jin Yanling, Royer-Joo Stephanie, Peters Ubong, Shankar Noopur, Schutzman Jennifer L, Juric Dejan
Abstract excerpt
PURPOSE: To investigate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of inavolisib, a potent and selective small-molecule inhibitor of p110α that promotes the degradation of mutated p110α, in combination with palbociclib and endocrine therapy (ET), in a phase I/Ib study in patients with PIK3CA-mutated, hormone receptor-positive/human epidermal growth factor receptor...
Topics
Join the communities discussing this publication.